Dark

Check out our Dark Pool Levels

AVTE
Aerovate Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive

Apr 28, 2025

93.80USD0.000%(0.00)29,370

Pre-market

0.00USD-100.000%(-93.80)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 25, 2022

06:51AM EST Aerovate Therapeutics Granted U.S. Patent #11,229,650 'Inhalable imatinib formulations, manufacture, and uses thereof' Benzinga

Dec 15, 2021

08:05AM EST Aerovate Therapeutics Announces Initiation Of IMPAHCT Phase 2b/Phase 3 Trial Of AV-101 In Pulmonary Arterial Hypertension Benzinga

08:00AM EST Aerovate Therapeutics Announces Initiation of IMPAHCT Phase GlobeNewswire Inc

Nov 15, 2021

11:09AM EST Aerovate Therapeutics Q3 EPS $(0.26) Benzinga

08:00AM EST Aerovate Therapeutics, Inc.(Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced our financial results for the quarter ended September 30, 2021, and recent events. GlobeNewswire Inc

Oct 18, 2021

10:28AM EDT Mid-Morning Market Update: Markets Mostly Lower; Albertsons Tops Q2 Estimates Benzinga

Sep 17, 2021

08:05AM EDT Aerovate Therapeutics To Join Russell 2000 Index, Effective Date Not Given Benzinga

08:00AM EDT Aerovate Therapeutics, Inc.(Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, announced it has been added to the Russell 2000 Index, effective after the markets close today, following the recent Russell US Indexes annual reconstitution. GlobeNewswire Inc

Sep 6, 2021

11:49AM EDT Aerovate Therapeutics-Sponsored Study 'A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)' Posted to Clinical Trials Website; Study is Not Yet Recruiting Benzinga

Aug 26, 2021

08:09AM EDT The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO Benzinga

Aug 24, 2021

08:09AM EDT The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal Benzinga

Aug 16, 2021

08:18AM EDT Aerovate Therapeutics Q2 EPS $(23.80), Down From $(9.12) Benzinga

08:00AM EDT Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced its financial results for the quarter ended June 30, 2021, and recent events. GlobeNewswire Inc

Jul 29, 2021

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 26, 2021

10:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2021 Benzinga

09:07AM EDT Evercore ISI Group Initiates Coverage On Aerovate Therapeutics with Outperform Rating, Announces Price Target of $30 Benzinga

08:46AM EDT Cowen & Co. Initiates Coverage On Aerovate Therapeutics with Outperform Rating Benzinga

06:12AM EDT Wedbush Initiates Coverage On Aerovate Therapeutics with Outperform Rating, Announces Price Target of $23 Benzinga

06:02AM EDT Jefferies Initiates Coverage On Aerovate Therapeutics with Buy Rating, Announces Price Target of $21 Benzinga

Jul 22, 2021

11:34AM EDT The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, Absci IPO Benzinga

Jul 21, 2021

07:52AM EDT The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 19, 2021

08:00AM EDT Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Allison Dorval, chief financial officer of Voyager Therapeutics, Inc. (Voyager), as a member of Aerovates Board of Directors. GlobeNewswire Inc

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 13, 2021

06:17PM EDT Last IPO Week Was The Busiest In Over A Decade Benzinga

05:59PM EDT A Shortened IPO Holiday Week Benzinga

08:05AM EDT The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jul 2, 2021

04:01PM EDT Aerovate Therapeutics Announces Closing of Initial Public Offering GlobeNewswire Inc

07:38AM EDT The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures Benzinga

Jun 30, 2021

03:37PM EDT Drug Formulation Developer Aerovate Therapeutics Kick Starts Trading Today With Upsized Debut Benzinga

02:36PM EDT Mid-Afternoon Market Update: Dow Jumps 190 Points; Altimmune Shares Plummet Benzinga

12:23PM EDT Mid-Day Market Update: Barnes & Noble Education Drops Following Q4 Results; Aerovate Therapeutics Shares Surge Benzinga

10:50AM EDT Aerovate Therapeutics Shares Open For Trade At $28; IPO Priced At $14/Share Benzinga

10:44AM EDT Aerovate Therapeutics Shares Indicating $28 Benzinga

09:24AM EDT Aerovate Therapeutics Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced At $14/Share Benzinga

Jun 29, 2021

10:59PM EDT Aerovate Therapeutics Announces Pricing of Upsized Initial Public GlobeNewswire Inc

Share